Filana Therapeutics (FLNA) Price to Sales (2010 - 2013)

Filana Therapeutics has reported Price to Sales for 4 years, with the latest figure at 43.93 in Q4 2013.

• On a quarterly basis, Price to Sales fell 87.22% year-over-year to 43.93 in Q4 2013; TTM through Dec 2013 was 37.65, a 51.68% decrease from a year earlier, with the FY2013 full-year figure at 37.65, down 51.68% from the prior year.
• Price to Sales was 43.93 for Q4 2013 at Filana Therapeutics, down from 441.85 in the prior quarter.
• The five-year high for Price to Sales was 891.8 in Q1 2011, with the low at 43.93 in Q4 2013.
• Average Price to Sales over 4 years is 471.43, with a median of 441.85 recorded in 2013.
• The sharpest annual moves came in 2011 and 2013: Price to Sales jumped 71.1% in 2011, then tumbled 87.22% in 2013.
• Over 4 years, Price to Sales stood at 253.15 in 2010, then surged by 71.1% to 433.15 in 2011, then fell by 20.62% to 343.83 in 2012, then sank by 87.22% to 43.93 in 2013.
• The last three Price to Sales figures came in at 43.93 (Q4 2013), 441.85 (Q3 2013), and 358.82 (Q2 2013), per Business Quant data.